Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $25.6B | $28.2B | $32.8B | $33.3B | $45.8B | $56.2B | $58.1B | $54.3B | $56.3B | $61.2B |
| Revenue growth | — | 10.1% | 16.1% | 1.6% | 37.7% | 22.7% | 3.3% | -6.4% | 3.7% | 8.6% |
| Operating income | $9.34B | $9.54B | $6.38B | $13.0B | $11.4B | $17.9B | $18.1B | $12.8B | $9.14B | $15.1B |
| Operating margin | 36.4% | 33.8% | 19.5% | 39.0% | 24.8% | 31.9% | 31.2% | 23.5% | 16.2% | 24.6% |
| Net income | $5.95B | $5.31B | $5.69B | $7.88B | $4.62B | $11.5B | $11.8B | $4.86B | $4.28B | $4.23B |
| Net margin | 23.2% | 18.8% | 17.4% | 23.7% | 10.1% | 20.5% | 20.4% | 9.0% | 7.6% | 6.9% |
| EPS (diluted) | $3.63 | $3.30 | $3.66 | $5.28 | $2.72 | $6.45 | $6.63 | $2.72 | $2.39 | $2.36 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $7.04B | $9.96B | $13.4B | $13.3B | $17.6B | $22.8B | $24.9B | $22.8B | $18.8B | $19.0B |
| Capital expenditures | $479M | $529M | $638M | $552M | $798M | $787M | $695M | $777M | $974M | $1.21B |
| Free cash flow | $6.56B | $9.43B | $12.8B | $12.8B | $16.8B | $22.0B | $24.2B | $22.1B | $17.8B | $17.8B |
| Share buybacks | $6.03B | $1.41B | $12.0B | $629M | $978M | $934M | $1.49B | $1.97B | $1.71B | $980M |
| Dividends paid | $3.72B | $4.11B | $5.58B | $6.37B | $7.72B | $9.26B | $10.0B | $10.5B | $11.0B | $11.7B |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $5.10B | $9.30B | $7.29B | $39.9B | $8.45B | $9.75B | $9.20B | $12.8B | $5.52B | $5.23B |
| Total assets | $66.1B | $70.8B | $59.4B | $89.1B | $151B | $147B | $139B | $135B | $135B | $134B |
| Long-term debt | — | — | — | $67.2B | $84.9B | $76.0B | $63.1B | $59.2B | $66.8B | $64.5B |
| Shareholders' equity | $4.64B | $5.10B | -$8.45B | -$8.17B | $13.1B | $15.4B | $17.3B | $10.4B | $3.33B | -$3.27B |
| Retained earnings | $4.38B | $5.46B | $3.37B | $4.72B | $1.05B | $3.13B | $4.78B | -$1.00B | -$7.90B | -$15.5B |
| Shares (wtd avg diluted) | 1.63B | 1.60B | 1.55B | 1.48B | 1.67B | 1.78B | 1.78B | 1.77B | 1.77B | 1.77B |
Every figure is extracted from AbbVie Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.